Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $11.64 Consensus Target Price from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average recommendation of “Buy” by the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $11.6364.

A number of equities analysts have issued reports on the stock. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen upgraded Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th.

Taysha Gene Therapies Trading Up 8.1%

Shares of TSHA opened at $6.43 on Wednesday. The stock’s fifty day simple moving average is $4.63 and its 200-day simple moving average is $4.77. The firm has a market capitalization of $1.85 billion, a PE ratio of -18.91 and a beta of 1.10. Taysha Gene Therapies has a 12-month low of $1.22 and a 12-month high of $6.50. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. As a group, research analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kamran Alam sold 78,968 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $375,098.00. Following the completion of the transaction, the chief financial officer owned 1,467,635 shares of the company’s stock, valued at $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 598,623 shares of company stock valued at $2,772,188 in the last 90 days. 3.78% of the stock is owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP boosted its stake in Taysha Gene Therapies by 150.0% in the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock worth $75,625,000 after purchasing an additional 8,250,000 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at about $11,178,000. Barclays PLC lifted its holdings in shares of Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $20,471,000. Finally, State Street Corp boosted its position in shares of Taysha Gene Therapies by 49.1% during the fourth quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after buying an additional 3,553,619 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.